NOVOBIOTIC PHARMACEUTICALS, LLC
Doing business as NOVOBIOTIC PHARMACEUTICALS LLC
- CAMBRIDGE, MA 02138-1068
- novobiotic.com (company website, opens in a new tab)
- Partnership or Limited Liability Partnership
- SAM expiring
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
SAM.gov registration expires in 49 days
NOVOBIOTIC PHARMACEUTICALS, LLC’s registration expires on Jan 2, 2027. Renewal can take weeks; confirm it stays active through proposal submission and award.
View on SAM.gov (opens in a new tab)Learn more about SAM registration and the UEI
About NOVOBIOTIC PHARMACEUTICALS, LLC
- Headquarters
- CAMBRIDGE, MA 02138-1068
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIGUV4CZLZE5Z2
- CAGE48R19
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 25 awards
- Total awarded
- $36,654,092
- By phase
- SBIR Phase I: 16
- SBIR Phase II: 9
- By agency
- Department of Health and Human Services: 24
- National Science Foundation: 1
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2023: 1
- 2022: 1
- 2020: 2
- 2019: 1
- 2018: 2
- 2017: 1
- 2016: 1
- 2015: 3
- 2014: 1
- 2013: 2
- 2012: 1
- 2010: 3
- 2009: 1
- 2008: 1
- 2007: 1
- 2006: 1
- 2005: 1
- 2004: 1
Awards (most recent first)
Antifungal discovery from previously uncultivated bacteria
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $595,754
May 9, 2023 – Apr 30, 2025
Solicitation PA22-176 (2022) · Topic NIAID
Teixobactin Development for Tuberculosis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $2,988,753
Sep 1, 2022 – Aug 31, 2025
Solicitation PA21-259 (2021) · Topic NIAID
Teixobactin Development for Anthrax
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2020 · $2,989,150
Jun 15, 2020 – May 31, 2023
- Direct to Phase II
Solicitation PA19-272 (2019) · Topic R
Antibiotic discovery from a new genus of uncultured bacteria.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $596,026
Apr 22, 2020 – Mar 31, 2022
Solicitation PA19-272 (2019) · Topic NIAID
Preclinical development of Novo29, a new antibiotic
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $2,964,879
Apr 15, 2019 – Mar 31, 2022
Solicitation PA18-574 (2018) · Topic NIAID
Preclinical development of teixobactin, a new antibiotic
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $2,995,488
Feb 14, 2018 – Jan 31, 2021
Solicitation PA17-302 (2017) · Topic R
Preclinical development of Novo29, a new antibiotic
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $231,409
Jan 10, 2018 – Jun 30, 2018
Solicitation PA16-302 (2016) · Topic R
Novel Antibiotics from Marine Invertebrate Microbes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $586,229
Aug 9, 2017 – Jul 31, 2019
Solicitation PA16-302 (2016) · Topic NIAID
Exploratory Chemistry on a new antibiotic
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,484,593
Jun 16, 2016 – May 31, 2019
Solicitation PAR14-088 (2014) · Topic NIAID
Microbial symbionts of marine invertebrates for antibiotic discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $224,356
Jul 1, 2015 – Dec 31, 2015
Solicitation PA14-071 (2015) · Topic NIAID
Specific anti-TB compounds from uncultured bacteria
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $219,069
Feb 1, 2015 – Jul 31, 2015
Solicitation PA14-071 (2015) · Topic NIAID
Preclinical development of teixobactin, a new antibiotic
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2015 · $1,490,624
Feb 1, 2015 – Jan 31, 2018
- Direct to Phase II
Solicitation PAR14-088 (2017) · Topic NIAID
Selective agents against C. difficile infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $597,402
May 1, 2014 – Apr 30, 2016
Solicitation PA10-123 (2015) · Topic NIAID
SBIR Phase I: Novel Antibiotics from Marine Animal-Microbe Symbioses
SBIR Phase I · National Science Foundation · 2013 · $147,276
Jan 1, 2013 – Dec 31, 2013
Solicitation year 2012 · Topic BC · Research partner: Stub
Drug Discovery from Slow Growing and Rare Microbial Species
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $2,967,717
Dec 15, 2012 – Nov 30, 2015
Solicitation PA10-123 (2013) · Topic NIAID
UV-Based Approach for Accessing New Antibiotics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $599,946
Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub
High throughput antibiotic discovery from the uncultivated microbial majority.
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $597,943
Solicitation PHS2010-2 (2010) · Topic NIAID
Drug Discovery from Slow Growing and Rare Microbial Species
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $598,976
Solicitation PHS2010-2 (2010) · Topic NIAID
Isolating novel fungi for antibiotic discovery
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2010 · $2,998,500
Solicitation PHS2010-2 (2010) · Topic NIAID
Isolating novel actinomycetes for antibiotic discovery
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2009 · $2,998,360
Solicitation PHS2009-2 (2009)
Isolating novel actinomycetes for antibiotic discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $598,617
Solicitation PHS2007-2 (2008)
Isolating novel fungi for antibiotic discovery
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $299,258
Solicitation year 2007
Developing Novel Antibiotics Against Yersinia pestis
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2006 · $5,412,780
Solicitation PHS2006-2 (2006)
Novel Approaches to Accessing Secondary Metabolites
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2005 · $999,578
Solicitation PHS2005-2 (2005)
Developing Novel Antibiotics Against Yersinia pestis
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2004 · $471,409
Solicitation PHS2004-2 (2004)
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
No active exclusion on record (checked Nov 14, 2026).
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · as of Nov 14, 2026
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 238990All Other Specialty Trade ContractorsPrimary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with NOVOBIOTIC PHARMACEUTICALS, LLC?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.